It’s becoming increasingly clear that it will take much longer before a coronavirus vaccine is made available for the masses. Johnson & Johnson (NYSE:JNJ) is the latest drugmaker to hit a major stumbling block on developing its novel coronavirus vaccine. The drugmaker has had to pause ongoing clinical trials after a volunteer developed an explained illness.
JNJ Disappointment
Likewise, the company has halted Phase 3 trials as it tries to investigate the matter further. While it is unknown whether the illness is related to the vaccine, it could take much longer, which could derail the Phase 3 trials.
Johnson & Johnson’s JNJ-78436735 was one of the four vaccines in the final stage of testing, fuelling hope of a positive outcome. However, its prospects now hang in the balance as clinical protocols require a pause until all the issues are investigated.
With any clinical trials, adverse events are often expected among participants. However, such studies have pre-specified guidelines that companies must follow. The guidelines also specify when a trial -would be shut down until everything is sorted out.
Coronavirus Vaccine Uncertainty
In the case of Johnson & Johnson, the Independent Data Safety Monitoring Board, which was overseeing the trial, is set to review what happened and decide whether it is safe to resume trials. Johnson n Johnson is yet to specify what the illness was.
The drugmaker joins AstraZeneca plc. (NASDAQ:AZN), which was forced to halt Phase 3 trials in September after a second participant was diagnosed with a neurological condition after taking the candidate coronavirus vaccine. The halting of the two trials means there are only two vaccine trials in Phase 3.
A coronavirus vaccine is highly needed when the world appears to be struggling amid the second wave of infections. More than 1 million people have already succumbed to the deadly virus worldwide, with the U.S leading with more than 200k deaths. Infections have already clocked 37 million and could edge higher heading into the winter season.